BioSpace News Archive

Reneo Pharmaceuticals, Inc. announced two poster presentations at the International Network for Fatty Acid Oxidation Research and Management (INFORM) annual meeting, being held in Freiburg, Germany August 28-29, 2022.

RedCloud Bio (the “Company”), an innovative biotech company integrating structural pharmacology and computational approaches to advance small molecule drug discovery and development, announced completion of the first patient dosing for its next-generation EGFR TKI H002 in its H002-101CN study.

Centessa Pharmaceuticals plc today announced that members of its management team will participate in the following investor conferences.

Pharmazz, Inc. (“Pharmazz”), a biopharmaceutical company focused on developing and commercializing novel therapeutics to treat patients in critical care, today announced the clearance of an Investigational New Drug (IND) application by the India Central Drugs Standard Control Organization (CDSCO) to conduct a Phase II clinical trial of sovateltide in hypoxic-ischemic encephalopathy (HIE) in neonates.

Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that it will be participating in investor meetings at the Citi 17th Annual BioPharma Conference at the Four Seasons Hotel in Boston on September 8, 2022.

Timber Pharmaceuticals, Inc. today announced that seven abstracts detailing positive clinical data from the completed Phase 2b CONTROL study of TMB-001 were accepted for e-poster presentation at the 31st European Academy of Dermatology and Venerology (EADV) Congress, which will be held in Milan, Italy and virtually from September 7-10, 2022.

Enlivex Therapeutics Ltd. today announced that the Japanese Patent Office issued a Notice of Allowance for patent application number 2020-198242.

AbbVie (NYSE: ABBV) today announced it will present 23 abstracts at the 31st European Academy of Dermatology and Venereology (EADV) Congress.

AllianceRx Walgreens Pharmacy, one of the largest specialty and home delivery pharmacies in the country, is excited to be one of two specialty pharmacies Nobelpharma America, LLC, has selected to distribute its rare disease drug HYFTOR™ 0.2%.

NewAmsterdam Pharma today announced emerging data adding to the growing body of clinical evidence supporting a shift in the treatment paradigm towards prioritizing a combination approach as first-line therapy for very high-risk atherosclerotic cardiovascular disease (ASCVD) patients.